Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 34mf9 | — |
Inadvertent administration of Kinrix under 4 years; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 19-month-old male patient who received DTPa-IPV (Kinrix) (batch number 34mf9, expiry date 13-FEB-2026) for prophylaxis. Previously administered products included Kinrix (patient has 4 Dtaps now), Kinrix (patient has 4 Dtaps now) and Kinrix (patient has 4 Dtaps now). On 14-MAR-2025, the patient received Kinrix. On 14-MAR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Inadvertent administration of Kinrix under 4 years). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 14-APR-2025 Other HCP reported that a 19 months old baby received Kinrix, which led to inappropriate age at vaccine administration. Counting this last Kinrix shot, patient has 4 Dtaps now and asked How to proceed